<?xml version="1.0" encoding="UTF-8"?>
<ref id="B121-pharmaceutics-13-00387">
 <label>121.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Gobetti</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Balsan</surname>
    <given-names>M.E.</given-names>
   </name>
   <name>
    <surname>Ayres</surname>
    <given-names>M.V.</given-names>
   </name>
   <name>
    <surname>De Almeida</surname>
    <given-names>S.H.O.</given-names>
   </name>
   <name>
    <surname>Simon</surname>
    <given-names>E.D.S.</given-names>
   </name>
   <name>
    <surname>Wingert</surname>
    <given-names>N.R.</given-names>
   </name>
   <name>
    <surname>Oppe</surname>
    <given-names>T.P.</given-names>
   </name>
   <name>
    <surname>Garcia</surname>
    <given-names>C.V.</given-names>
   </name>
  </person-group>
  <article-title>Development and Stability Control of Pediatric Oral Tizanidine Hydrochloride Formulations for Hospital Use</article-title>
  <source>AAPS PharmSciTech</source>
  <year>2020</year>
  <volume>21</volume>
  <fpage>1</fpage>
  <lpage>11</lpage>
  <pub-id pub-id-type="doi">10.1208/s12249-020-01751-8</pub-id>
 </element-citation>
</ref>
